Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Efecto de atorvastatina sobre los valores de fibrinógeno en pacientes con diabe...
Información de la revista
Vol. 52. Núm. 7.
Páginas 333-337 (Septiembre 2005)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 52. Núm. 7.
Páginas 333-337 (Septiembre 2005)
Originales
Acceso a texto completo
Efecto de atorvastatina sobre los valores de fibrinógeno en pacientes con diabetes mellitus tipo y 2 dislipemia
Effect of atorvastatin on plasma fibrinogen levels in patients with type 2 diabetes mellitus and dyslipidemia
Visitas
...
F. Illána,??
Autor para correspondencia
mariaf.illan@carm.es

Correspondencia: Dr. F. Illán. Sección de Endocrinología y Nutrición. Hospital Universitario Morales Meseguer. Avda. Marqués de los Vélez, s/n. 30008 Murcia. España.
, M.S. Alcarazaa, M. Pascuala, I. Oreaa, A. Carrillob
a Sección de Endocrinología y Nutrición. Hospital Universitario Morales Meseguer. Murcia. España
b Unidad de Investigación. Hospital Universitario Morales Meseguer. Murcia. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

La diabetes mellitus tipo 2 se asocia con un aumento de riesgo de enfermedad cardiovascular. Estudios prospectivos indican que valores elevados de fibrinógeno se relacionan con mayor riesgo de episodios cardiovasculares. Por este motivo, se ha examinado el efecto del tratamiento de la hiperlipemia con atorvastatina sobre el valor del fibrinógeno en pacientes con diabetes mellitus tipo 2.

Pacientes y métodos

Se ha evaluado el fibrinógeno basal y tras 6 meses de tratamiento con 20 mg al día de atorvastatina en 45 pacientes con diabetes mellitus tipo 2 no fumadores con hiperlipemia. Se obtuvieron datos clínicos y analíticos.

Resultados

Los valores de fibrinógeno disminuyeron significativamente tras tratamiento con atorvastatina (media=−0,60 g/l; p<0,001). Se observa una correlación entre los valores basales de fibrinógeno y microalbuminuria (r=0,349; p<0,05). La reducción del fibrinógeno se correlacionó de forma significativa con los valores basales de fibrinógeno (r=0,407; p<0,05) y la hemoglobina glucosilada basal (r=0,369; p<0,05) pero no se relacionó con la disminución del colesterol ligado a lipoproteínas de baja densidad (cLDL).

Conclusión

Hemos comprobado una disminución de las concentraciones plasmáticas de fibrinógeno en diabéticos tipo 2 con dislipemia tras tratamiento con atorvastatina, que es independiente de la reducción del cLDL.

Palabras clave:
Fibrinógeno
Diabetes mellitus tipo 2
Atorvastatina
Inflamación
Hiperlipemia
Introduction

Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease. Prospective studies indicate that fibrinogen levels are associated with an increased risk for cardiovascular events. Therefore, we tested the effect of atorvastatin on fibrinogen levels in patients with type 2 diabetes mellitus.

Patients and methods

Fibrinogen was evaluated at baseline and after 6 months of therapy with 20 mg atorvastatin daily in 45 non-smoking patients with type 2 diabetes mellitus and hyperlipidemia. Clinical and biochemical data were obtained.

Results

Fibrinogen levels were significantly decreased after treatment with atorvastatin compared with baseline (mean change: −0.60 g/L; p<0.001). A correlation between baseline fibrinogen levels and microalbuminuria was found (r=0.349; p<0.05). Fibrinogen reduction was significantly correlated with baseline fibrinogen levels (r=0.407, p<0.05) and baseline glycosylated hemoglobin values (r=0.369, p<0.05). Conversely, no significant correlation was found between fibrinogen reduction and change in lowdensity lipoprotein (LDL)-cholesterol.

Conclusion

Plasma fibrinogen levels decreased in patients with type 2 diabetes and hyperlipidemia treated with atorvastatin. This decrease was largely independent of LDL-cholesterol reduction.

Key words:
Fibrinogen
Type 2 diabetes mellitus
Atorvastatin
Inflammation
Hyperlipidemia
El Texto completo está disponible en PDF
Bibliografía
[1.]
T.W. Meade, W.R.S. North, R. Chakrabarti, Y. Stirling, A.P. Haines, S.G. Thompson, et al.
Haemostatic function and cardiovascular death: early results of a prospective study.
Lancet, 1 (1980), pp. 1050-1053
[2.]
UKPDS Group.
Intensive blood control with sulfonil-ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 857-865
[3.]
S.I. McFarlane, R. Muniyappa, R. Francisco, J.R. Sowers.
Pleiotropic effects of statins: Lipid reduction and beyond.
J Clin Endocrinol Metab, 87 (2002), pp. 1451-1458
[4.]
W.B. Kannel, P.A. Wolf, W.P. Castelli, R.B. D’Agostino.
Fibrinogen and risk of cardiovascular disease: the Framingham Study.
JAMA, 9 (1987), pp. 1183-1186
[5.]
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group.
Lancet, 344 (1994), pp. 1383-1389
[6.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. Mac- Farlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
N Engl J Med, 333 (1995), pp. 1301-1307
[7.]
R. Krysiak, B. Okopien, Z.S. Herman.
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Drugs, 63 (2003), pp. 1821-1854
[8.]
P. Miossec, F. Zkhiri, J. Paries, M. David-Dufilho, M.A. Devyinck, P.E. Valensi.
Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled type II diabetic patients.
Diabet Med, 16 (1999), pp. 424-430
[9.]
Y. Tsuda, K. Satoh, M. Kitadal, et al.
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Atherosclerosis, 122 (1996), pp. 225-233
[10.]
E. Rizos, G. Miltiadous, M. Elisaf.
The effect of fluvastatin on plasma fibrinogen.
Curr Med Res Opin, 18 (2002), pp. 154-155
[11.]
A. Branchi, A. Rovellini, D. Sommariva, A.G. Gugliandolo, A. Fasoli.
Effect of three fibrate derivaties and two HMG-COA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Thromb Haemostasis, 70 (1993), pp. 241-243
[12.]
A.D. Marais, J.C. Firth, M.E. Bateman, P. Byrnes, C. Martens, J. Mountney.
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Atheroscler Thromb Vasc Biol, 17 (1997), pp. 1527-1531
[13.]
A.S. Wierzbicki, P.J. Lumb, Y.K. Semra, M.A. Crook.
Effect of atorvastatin on plasma fibrinogen.
Lancet, 351 (1998), pp. 569-570
[14.]
V.G. Athyros, A.A. Papageorgiou, H.A. Hatzikonstandinou, W. Athyron, A.G. Kontopoulos.
Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia.
Clin Drug Invest, 16 (1998), pp. 219-227
[15.]
M. Davidson, J. McKenney, E. Stein, H. Schrott, R. Bakker-Arkema, R. Fayyad, et al.
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia.
Am J Cardiol, 79 (1997), pp. 1475-1481
[16.]
C. Bickel, H.J. Rupprecht, S. Blankenberg, C. Espiniola-Klein, A. Schlitt, G. Rippin, et al.
Relation of markers of inflammation (C-reactive protein, fibrinogen, von Villebrand factor, and leukocyte count) and statin therapy to long-term mortalirty in patients with angiographicall proven coronary artery disease.
Am J Cardiol, 89 (2002), pp. 901-908
[17.]
J.A. Goudevenos, E.T. Bairaktari, K.G. Chatzidimou, H.J. Milionis, D.P. Mikhaidilis, M.S. Elisaf.
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dislipidaemia-a pilot study involving serial sampling.
Curr Med Res Opin, 16 (2001), pp. 269-275
[18.]
M. Davis, A.S. Atwal, D.R. Nair, I.A. Jagroop, A.M. Seifalian, D.P. Mikhailidis, et al.
The effect of short term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study.
Curr Med Res Opin, 16 (2000), pp. 198-204
[19.]
C. Le Dévéhat, T. Khodabandehlou, M. Vimeux.
Diabete sucré et fibrinogéne: consequences hémorhéologique et microcirculatoire.
J Mal Vas, 24 (1999), pp. 31
[20.]
S.E. Humphries.
Genetic regulation of fibrinogen.
Eur Heart J, 16 (1995), pp. 16-20
[21.]
J.C. Song, C.M. White.
Do HMG-CoA reductase inhibitors affect fibrinogen?.
Ann Pharmacother, 35 (2001), pp. 236-241
[22.]
P. Libby, P.M. Ridker, A. Maseri.
Inflammation and atherosclerosis.
Circulation, 105 (2002), pp. 1135-1143
[23.]
P.A. Sakkinen, P. Wahl, M. Cushman, M.R. Lewis, R.P. Tracy.
Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome.
Am J Epidemiol, 152 (2000), pp. 897-907
[24.]
S. Agewall, J. Wikstrand, S. Ljungman, B. Faberberg.
Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group.
Am J Cardiol, 80 (1997), pp. 164-169
[25.]
D. Streja, P. Cressey, S.W. Rabkin.
Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus.
J Diabetes Complications, 17 (2003), pp. 120-127
[26.]
F. Green, S. Humphries.
Control of plasma fibrinogen levels.
Bailliéres Clin Haematol, 2 (1989), pp. 945-949
[27.]
G.J. Miller.
Lipoproteins and thrombosis: effects of lipid lowering.
Curr Opin Lipidol, 6 (1995), pp. 38-42
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos